Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
RESEARCH TOOLSreports
BTAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.16 - $61.12
Previous CloseN/A
Volume1.10M
Average Volume (3M)214.05K
Market Cap
$7.17M
Enterprise Value$90.44M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Mar 06, 2025EPS Estimate
-6.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-34.43
Shares Outstanding3,101,809
10 Day Avg. Volume264,347
30 Day Avg. Volume214,048
Standard Deviation0.30
R-Squared0.00
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.15
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap12.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit753.67
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$37.00Price Target Upside1501.73% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Bioxcel Therapeutics News
PremiumCompany Announcements
Bioxcel Therapeutics Appoints Dr. Rajiv Patni to Board
PremiumCompany Announcements
Bioxcel Therapeutics Revises Executive Compensation Structure---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsGiven the solidity of the data in the SERENITY Phase 3 program, there is a relatively high chance that the FDA could approve at-home use for schizophrenia/bipolar disorder patients.
Financial ManagementBioxcel Therapeutics has successfully renegotiated its credit agreement, which helps address the company's cash concerns.
Treatment ApprovalBXCL501 is considered an attractive asset in the treatment of acute agitation for individuals with neuropsychiatric and neurodegenerative conditions.
Bears Say
Equity DilutionEquity dilution appears substantial, leading to a lowered price target.
Financial RisksThe company's financial situation is a major concern due to limited cash and the need to raise additional funds to meet debt covenants.
Sales PerformanceSales reported were roughly $214K, well below the $1.2M that was previously forecasted.
---
Ownership Overview
46.42% Insiders
4.16% Mutual Funds
0.10% Other Institutional Investors
46.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $2.16 and its highest was $61.12 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Bioxcel Therapeutics Inc’s market cap is $7.17M.
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Mar 06, 2025 which is in 15 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Nov 14, 2024. The company reported -$5.12 earnings per share for the quarter, beating the consensus estimate of -$8.089 by $2.969.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -6.38.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 3,101,809 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$5.12 in its last earnings report, beating expectations of -$8.089. Following the earnings report the stock price went down -15.859%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at 0.
---
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$37.00 (1501.73% Upside)
$37.00 (1501.73% Upside)
Blogger Sentiment
Bullish
BTAI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 22.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.34%
12-Months-Change
Fundamentals
Return on Equity
82.91%
Trailing 12-Months
Asset Growth
-51.33%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
---
BTAI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted progress in clinical trials and significant financial improvements, such as reduced net loss and increased revenue over the nine-month period. However, challenges remain with decreased quarterly revenue, increased costs, and uncertainties regarding cash runway and financing.Read More>---
BTAI Stock 12 Month Forecast
Average Price Target
$37.00
▲(1501.73% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Corcept Therapeutics
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering BTAI
1 Year
1 Year Success Rate
12/40 ratings generated profit
1 Year Average Return
+33.58%
reiterated a buy rating 2 months ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +33.58% per trade.
---